Seko Yuya, Moriguchi Michihisa, Hara Tasuku, Kataoka Seita, Okuda Keiichiroh, Furuta Mitsuhiro, Takemura Masashi, Taketani Hiroyoshi, Umemura Atsushi, Nishikawa Taichiro, Yamaguchi Kanji, Yasui Kohichiroh, Minami Masahito, Itoh Yoshito
Department of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Department of Gastroenterology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Hepatol Res. 2019 Apr;49(4):473-478. doi: 10.1111/hepr.13296. Epub 2019 Jan 18.
The liver function of patients with hepatitis C virus (HCV) infection who obtained sustained virologic response (SVR) has been known to improve after HCV eradication. However, a predictor of liver function after SVR has not been definitively identified. The aim of this retrospective study was to identify a predictor of deteriorated liver function and Fibrosis-4 (FIB-4) index after SVR was achieved by direct-acting antiviral (DAA) treatment.
This study retrospectively enrolled 248 patients who obtained SVR by DAA treatment. None of the patients developed hepatocellular carcinoma during this study. Liver function was assessed at the end of treatment (EOT) and at 24, 48, 72, and 96 weeks after EOT.
At 96 weeks after EOT, the serum aspartate aminotransferase and alanine aminotransferase levels were significantly decreased from those at EOT. The platelet count was significantly increased from 14.9 × 10 /μL at EOT to 17.1 × 10 /μL at 96 weeks after EOT. Ten patients showed an increased FIB-4 (>1.00) index. Multivariate analysis with 171 patients who underwent endoscopic assessment revealed that the presence of varices was an independent predictor of deterioration in the FIB-4 index (odds ratio, 5.56; P = 0.041).
Most of the study patients who obtained SVR showed improved liver function after EOT. Patients without increasing platelet counts after SVR due to DAA therapy should be evaluated for complications induced by portal hypertension.
已知丙型肝炎病毒(HCV)感染患者获得持续病毒学应答(SVR)后,其肝功能在HCV根除后会有所改善。然而,SVR后肝功能的预测指标尚未明确确定。这项回顾性研究的目的是确定直接抗病毒药物(DAA)治疗实现SVR后肝功能恶化和纤维化-4(FIB-4)指数的预测指标。
本研究回顾性纳入了248例通过DAA治疗获得SVR的患者。在本研究期间,所有患者均未发生肝细胞癌。在治疗结束时(EOT)以及EOT后24、48、72和96周评估肝功能。
在EOT后96周,血清天冬氨酸转氨酶和丙氨酸转氨酶水平较EOT时显著降低。血小板计数从EOT时的14.9×10⁹/μL显著增加至EOT后96周时的17.1×10⁹/μL。10例患者的FIB-4指数升高(>1.00)。对171例接受内镜评估的患者进行多变量分析显示,静脉曲张的存在是FIB-4指数恶化的独立预测指标(比值比,5.56;P = 0.041)。
大多数获得SVR的研究患者在EOT后肝功能有所改善。对于因DAA治疗SVR后血小板计数未增加的患者,应评估门静脉高压引起的并发症。